Helen Yang, Oricell CEO
In push to expand its CAR-T therapies to US, China biotech Oricell raises additional $45M
Shanghai biotech Oricell has raised an additional $45 million to bankroll its preclinical and early-stage cancer cell therapies, it announced Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
